Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$104.83 USD

104.83
4,831,663

-1.96 (-1.84%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $104.84 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (155 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Zacks Equity Research

Is DXP Enterprises (DXPE) Outperforming Other Industrial Products Stocks This Year?

by Zacks Equity Research

Here is how DXP Enterprises (DXPE) and Life360 (LIF) have performed compared to their sector so far this year.

Zacks Equity Research

Is The Ensign Group (ENSG) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Ensign Group (ENSG) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Zacks Equity Research

Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Boston Scientific (BSX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Zacks Equity Research

Strength Seen in Brainsway (BWAY): Can Its 5.3% Jump Turn into More Strength?

by Zacks Equity Research

Brainsway (BWAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Sridatri Sarkar headshot

BSX Raises 2025 Financial Outlook: What's Backing It?

by Sridatri Sarkar

Boston Scientific lifts its 2025 sales and EPS outlook after a strong Q1, with cardiology and EP segments fueling major gains.

Zacks Equity Research

RGC Resources (RGCO) Surges 9.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

RGC Resources (RGCO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Strength Seen in Mobileye (MBLY): Can Its 11.6% Jump Turn into More Strength?

by Zacks Equity Research

Mobileye (MBLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Boston Scientific (BSX) Surpasses Market Returns: Some Facts Worth Knowing

by Zacks Equity Research

Boston Scientific (BSX) concluded the recent trading session at $102.36, signifying a +1.05% move from its prior day's close.

Zacks Equity Research

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Sridatri Sarkar headshot

BSX's Neuromodulation Arm Sees Growth: Q1 Highlights

by Sridatri Sarkar

Boston Scientific's Neuromodulation unit witnesses 6.8% growth in the first quarter, fueled by strong gains in pain and brain therapy lines.

Indrajit Bandyopadhyay headshot

ISRG vs BSX: Which Medical Device Stock Has More Room to Run?

by Indrajit Bandyopadhyay

Boston Scientific offers steady growth with broader exposure, while Intuitive Surgical leads in robotics but faces margin and tariff headwinds.

Zacks Equity Research

Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?

by Zacks Equity Research

Sector ETF report for IHI

Zacks Equity Research

Why the Market Dipped But Boston Scientific (BSX) Gained Today

by Zacks Equity Research

The latest trading day saw Boston Scientific (BSX) settling at $99.74, representing a +1.2% change from its previous close.

Zacks Equity Research

ATGE or UTI: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ATGE vs. UTI: Which Stock Is the Better Value Option?

Zacks Equity Research

AL vs. WAB: Which Stock Is the Better Value Option?

by Zacks Equity Research

AL vs. WAB: Which Stock Is the Better Value Option?

Zacks Equity Research

PAHC vs. BSX: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

PAHC vs. BSX: Which Stock Is the Better Value Option?

Zacks Equity Research

NEXA or WPM: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

NEXA vs. WPM: Which Stock Is the Better Value Option?

Zacks Equity Research

ODP or ULTA: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ODP vs. ULTA: Which Stock Is the Better Value Option?

Sridatri Sarkar headshot

BSX Q1 Endoscopy Sales Rise 6%: What's Behind the Growth?

by Sridatri Sarkar

Boston Scientific's Q1 2025 Endoscopy sales jump 6%, powered by innovation in stents, clips and surgical tools for GI care.

Sridatri Sarkar headshot

Cardiovascular Tailwind Boosts BSX: Here's How to Play the Stock

by Sridatri Sarkar

Boston Scientific rides strong cardiovascular momentum, with booming EP and WATCHMAN sales despite macro headwinds. What is the investment outlook?

Zacks Equity Research

Boston Scientific (BSX) Upgraded to Buy: Here's Why

by Zacks Equity Research

Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Boston Scientific (BSX) and Dare Bioscience, Inc. (DARE) have performed compared to their sector so far this year.

Zacks Equity Research

Wall Street Bulls Look Optimistic About Boston Scientific (BSX): Should You Buy?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Boston Scientific (BSX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Zacks Equity Research

Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors

by Zacks Equity Research

In the most recent trading session, Boston Scientific (BSX) closed at $102.43, indicating a -0.65% shift from the previous trading day.